NeuroCytonix has developed a cutting-edge medical biotechnology business focused on tissue engineering and regeneration. This technology and its related protocols are dramatically improving the treatment of nonprogressive neurodegenerative diseases including cerebral palsy, stroke, trauma brain injury, and spinal cord injury.
Dr. Trujillo has built an FDA-compliant Research Center in Monterrey Mexico where he has trained and directed an outstanding clinical research team, who are currently overseeing FDA trials.
We are currently conducting a double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of the NeuroCytotron in patients with cerebral palsy.
Dr. Trujillo's life mission of “curing the incurable” is coming to fruition.